Web Analytics Made Easy - StatCounter
Category

Anxiety Disorders

Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.

By | Anxiety Disorders, Behavioral Health

Authors: Alexandre Rafael de Mello Schier, Natalia Pinho de Oliveira Ribeiro, et al
Brazilian Journal of Psychiatry, June 2012

OBJECTIVES: To review and describe studies of the non-psychotomimetic constituent of Cannabis sativa, cannabidiol (CBD), as an anxiolytic drug and discuss its possible mechanisms of action. METHOD:
The articles selected for the review were identified through searches in Englis…

Read More

Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.

By | Anxiety Disorders, Behavioral Health

Authors: Simone Tambaro, Marco Bortolato
Recent Patents on CNS Drug Discovery, 1 April 2012

Rich evidence has shown that cannabis products exert a broad gamut of effects on emotional regulation. The main psychoactive ingredient of hemp, Δ9-tetrahydrocannabinol (THC), and its synthetic cannabinoid analogs have been reported to either attenuate or exacerbate anxiety an…

Read More

Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients.

By | Anxiety Disorders

Authors: Mateus M Bergamaschi, Regina Helena Costa Queiroz, Marcos Hortes Nisihara Chagas, Danielle Chaves Gomes de Oliveira, Bruno Spinosa De Martinis, Flávio Kapczinski, João Quevedo, et al.
Neuropsychopharmacology, May 2011

Generalized Social Anxiety Disorder (SAD) is one of the most common anxiety conditions with impairment in social life. Cannabidiol (CBD), one major non-psychotomimetic compound of the cannabis sativa plant, has shown anxiolytic effects both in humans and in animals. This preli…

Read More

Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report.

By | Anxiety Disorders, Behavioral Health

Authors: José Alexandre S Crippa, Guilherme Nogueira Derenusson, Thiago Borduqui Ferrari, et al
Journal of Psychopharmacology, January 2011

Animal and human studies indicate that cannabidiol (CBD), a major constituent of cannabis, has anxiolytic properties. However, no study to date has investigated the effects of this compound on human pathological anxiety and its underlying brain mechanisms. The aim of the prese…

Read More

Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.

By | Anxiety Disorders, Behavioral Health, Nervous System Diseases, Parkinsonian Disorders, Schizophrenia Spectrum

Authors: Antonio Waldo Zuardi
Brazilian Journal of Psychiatry, September 2008

OBJECTIVE: The aim of this review is to describe the historical development of research on cannabidiol. METHOD: This review was carried out on reports drawn from Medline, Web of Science and SciELO. DISCUSSION: After the elucidation of the chemical structure of cannabidiol in 1…

Read More

Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling.

By | Anxiety Disorders, Behavioral Health

Authors: Sachin Patel and Cecilia J. Hillard
Journal of Pharmacology and Experimental Therapeutics, July 2006

Extracts of Cannabis sativa have been used for their calming and sedative effects for centuries. Recent developments in drug discovery have suggested that modulation of neuronal endogenous cannabinoid signaling systems could represent a novel approach to the treatment of anxie…

Read More